钻孔尿激酶注入引流联合阿托伐他汀钙治疗慢性硬膜下血肿的临床研究

Clinical Research of Urokinase Injection Following Punch Drainage Combined with Oral Atorvastatin Calcium in the Treatment of Chronic Subdural Hematoma

目的探讨钻孔尿激酶注入引流联合阿托伐他汀钙对慢性硬膜下血肿的疗效及预后。方法收集我院自2014年1月~2016年12月收治的慢性硬膜下血肿患者230例,随机分为研究组和对照组,每组各115例。对照组患者给予单纯钻孔引流治疗,研究组给予钻孔尿激酶注入引流联合阿托伐他汀钙口服治疗,观察两组患者的疗效、血肿复发及并发症情况,以及患者的住院时间及住院费用。结果研究组患者的总有效率是96.65%,优于对照组患者的总有效率(84.35%)。研究组患者血肿复发率、总并发症发生率、住院费用及住院时间均低于对照组,差异均有统计学意义(P<0.01)。结论利用钻孔尿激酶注入引流联合阿托伐他汀钙口服治疗慢性硬膜下血肿,效果明显优于单纯钻孔引流治疗,使血肿复发率和术后并发症发生率明显降低,并缩短患者的住院时间,从而降低住院费用,值得临床推广应用。

Objective To investigate the efficacy and prognosis of urokinase injection following punch drainage combined with oral atorvastatin calcium in the treatment of chronic subdural hematoma. Methods From January 2014 to December 2016,a total of 230 patients with chronic dural hematoma were enrolled in this study,and were randomly divided into the study group and the control group,with 115 cases in each. The patients in the control group were treated with drilling and drainage only. And the study group was given urokinase injection following punch drainage combined with oral atorvastatin calcium. The curative effect,hematoma recurrence,complications,hospitalization time and the hospital costs were observed between the two groups.Results The total effective rate was 96. 65% in the study group and was better than 84. 35% of the control group. The hematoma recurrence rate,the total complication rate,hospitalization time and hospitalization cost were lower in the study group than that of the control group（P〈0. 01）. Conclusion It is effective and safe of the urokinase injection following punch drainage combined with oral atorvastatin calcium for the treatment of chronic subdural hematoma,with the advantages of less hematoma recurrences,less complications,less hospitalization time and less hospitalization costs. It is worthy of clinical application and promotion.